NASDAQ: SIGASiga Technologies Inc Stock
$5.99+0.07 (+1.18%)
Updated Apr 17, 2025
SIGA Price
$5.99
Fair Value Price
$17.87
Market Cap
$427.91M
52 Week Low
$4.95
52 Week High
$12.83
P/E
7.22x
P/B
1.98x
P/S
3.09x
PEG
2.49x
Dividend Yield
N/A
Revenue
$138.72M
Earnings
$59.21M
Gross Margin
77.4%
Operating Margin
54.84%
Profit Margin
42.7%
Debt to Equity
0.13
Operating Cash Flow
$49M
Beta
0.86
Next Earnings
May 5, 2025
Ex-Dividend
Apr 29, 2025
Next Dividend
May 15, 2025
SIGA Overview
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SIGA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
SIGA
Ranked#28 of 54
Ranked#28 of 54
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.36 | A | |
| $24.65 | A | |
| $13.76 | A |
Be the first to know about important SIGA news, forecast changes, insider trades & much more!
SIGA News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SIGA scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SIGA ($5.99) is undervalued by 66.47% relative to our estimate of its Fair Value price of $17.87 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
SIGA ($5.99) is significantly undervalued by 66.47% relative to our estimate of its Fair Value price of $17.87 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
SIGA ($5.99) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more SIGA due diligence checks available for Premium users.
Valuation
SIGA fair value
Fair Value of SIGA stock based on Discounted Cash Flow (DCF)
Price
$5.99
Fair Value
$17.87
Undervalued by
66.47%
SIGA ($5.99) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SIGA ($5.99) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SIGA ($5.99) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SIGA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
7.22x
Industry
20.48x
Market
27.98x
SIGA is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
SIGA is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
SIGA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.98x
Industry
1.99x
SIGA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SIGA price to earnings growth (PEG)
For valuing profitable companies with growth potential
SIGA is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
SIGA's financial health
Profit margin
Revenue
$81.5M
Net Income
$45.8M
Profit Margin
56.2%
SIGA's Earnings (EBIT) of $76.07M... subscribe to Premium to read more.
Interest Coverage Financials
SIGA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$244.3M
Liabilities
$28.5M
Debt to equity
0.13
SIGA's short-term assets ($231.04M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SIGA's short-term assets ($231.04M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SIGA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SIGA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$56.3M
Investing
-$17.8k
Financing
-$161.8k
SIGA's operating cash flow ($48.76M)... subscribe to Premium to read more.
Debt Coverage Financials
SIGA vs Pharmaceutical Stocks
Siga Technologies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.